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ABSTRACT
Introduction. Cervical dystonia is the most frequent form of focal dystonia. It is characterised by involuntary muscular con-
tractions resulting in abnormal head/neck and shoulder movements and postures, which can be associated with tremor and 
pain. Local intramuscular injections of botulinum toxin type A (BoNT-A) is the treatment of choice, being both effective and 
well-tolerated. However, a considerable number (c. 30%) of patients discontinue this treatment.
The aim of this review was to analyse the factors possibly responsible for treatment failures of cervical dystonia (CD), with special 
regard to the new classification known as the ‘Col-Cap’ concept and non-motor symptoms.
Clinical implications. Several factors analysed in this review are responsible for effective treatment: proper diagnosis of dysto-
nia and exclusion of pseudodystonias, correct recognition of dystonia pattern and identification of new patterns according to 
the Col-Cap concept, muscle selection and precise injections under electromyography (EMG) and/or ultrasonography (US) gui-
dance. Furthermore, concomitant diagnosis and treatment of non-motor symptoms such as depression, anxiety, fatigue, sleep 
problems, phobias and stigmatisation are crucial in obtaining the best overall effect of the treatment. Primary and secondary 
immunisation and non-responsiveness seem to be marginal problems nowadays due to a low potential of new BoNT-A formu-
lations to produce neutralising antibodies.
Future directions. There is a need for new and relevant scales combining the Col-Cap concept patterns with non-motor symp-
toms and quality of life. There is also a lack of specific rehabilitation protocols which could enhance BoNT-A treatment results.
Key words: cervical dystonia, Col-Cap concept, botulinum toxin, treatment failures, primary non-responsiveness, secondary 
non-responsiveness
Introduction
Cervical dystonia (CD) is a movement disorder cha-
racterised by involuntary, sustained or intermittent muscle 
contractions leading to abnormal head movements and/or 
positioning. It is accompanied by pain in 67–75% of patients 
[1]. Typical features include sensory trick and head tremors. 
A substantial number of patients (18–41%) demonstrate com-
plications manifesting in premature degenerative disorder of 
the cervical spine, discopathy or cervical myelopathy [2]. CD 
significantly reduces quality of life, affects the ability to work, 
and socially stigmatises patients [2–3]. Spontaneous remission 
occurs in up to 15% of patients and is usually temporal [5, 6], but 
may be triggered by botulinum neurotoxin type A (BoNT-A) 
treatment [4]. CD is the most common focal dystonia: 
a meta-analysis reveals that it affects a mean 4.98 of every 
100,000 people. However, a significant difference has been 
observed with regards to geographical location: in Japan the 
rate is 2.52, whereas in Europe it is 6.71 [5].
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Treatment of CD with BoNT-A is the treatment of choice 
as recommended by the American Academy of Neurology 
(AAN), with high effectiveness and safety profiles [6].
Double-blind, randomised clinical, as well as open, studies 
have shown that 50–85% of patients demonstrate a significant 
improvement [7–15]. A considerable number (c. 30%, range 
19-46%) of patients discontinue treatment once it appears to
be ineffective [16–20]. Treatment may be considered ineffective 
if neither the patient nor the therapist have observed a sati-
sfactory reduction of symptoms or if significant adverse effects
occur (e.g. dysphagia or neck muscles weakness), or when
clinical trials observe no significant score reduction in rating 
scales. Those most commonly used are the Tsui Scale and the 
Toronto Western Spasmodic Torticollis Rating Scale, TWSTRS.
This article aims to analyse the possible factors responsible 
for treatment failures, with special regard to the new classifi-
cation of CD known as the Col-Cap concept and non-motor 
symptoms.
Making a proper diagnosis
BoNT-A can be effective both in primary and secondary 
dystonia. However, the latter may require specific treatment to 
avoid fatal progression and outcome like e.g. Wilson’s disease. 
Therefore, a proper diagnosis is essential. Particular attention 
should be paid to pseudodystonias that mimic dystonia and 
do not respond to treatment. Revised definitions and an ex-
tended list of pseudodystonic postures was recently presented 
by Berlot et al. (Tab. 1) [21]. Pseudodystonic postures must 
be clearly differentiated from conditions related to muscles 
weakness which can result in a head-drop e.g. myasthenia, 
muscular dystrophy, and amyotrophic lateral sclerosis. Moreo-
ver, pathological anteflexion can be confusing (e.g. anteflexion 
in multiple system atrophy) because there is no consensus 
as to whether it is related to dystonia of flexors or myositis 
and weakness of neck extensors [22]. It has been speculated 
that neck extensor myopathy might follow mechanical over-
-stretching from flexor dystonia. There is evidence that even
muscles which are not under mechanical stress can develop 
myopathic changes. Pathologic changes seen in inflammatory 
myopathies (IBM) have been found in clinically affected pa-
raspinal muscles. This shows the neurodegenerative nature of 
both IBM and parkinsonism.
Additionally, functional CD may be refractory to BoNT-A 
treatment. It usually presents as fixed dystonia or is multidi-
rectional, variable with different patterns at the same time, 
accompanied by enormous effort put into head positioning, 
with improvement after distraction, and no sensory twitches.
Table 1. Summary of possible causes of non-responsiveness or unsatisfactory effect of Botulinum toxin type A treatment of cervical dystonia
1. Primary non-responsiveness
 — preexisting BoNT-A antibodies, chronic exposure to BoNT-A in childhood, cross-reaction of other antibodies (e.g. tetanus toxin)
2. Secondary non-responsiveness
— neutralizing antibodies
— change in the pattern of dystonia, conditioned by the central mechanism of non-specific muscle activation
3. Misdiagnosis
 — dystonia in neurodegenerative diseases (PSP — usually retrocollis, MSA —  usually  anterocollis)
 — genetic disorders: Wilson’s disease, Huntington’s disease, spinocerebellar ataxias, neuroacanthocytosis, NBIA
 — dystonia in mitochondrial disorders
 — secondary dystonia caused by identified factors: post-traumatic dystonia, post-stroke dystonia, post-inflammatory dystonia, tardive dystonia, 
toxin-related dystonia
 — functional dystonia (psychogenic)
 — pseudodystonias:
a. related to musculoskeletal deformations: camptocormia, scoliosis, Grisel’s syndrome, Arnold-Chiari  syndrome, Klippel-Feil syndrome, joints 
deformities, arthrogryposis, Dupuytren’s contracture, congenital muscular torticollis, Sandifer’s syndrome,
b. related to the compensation of improper functioning of the central nervous system or peripheral nervous system (compensatory head tilt):
vestibular system disorder, oculomotor nerves palsies (6th, 4th), mass lesion in the posterior fossa
c. disorders of sensory pathways: parietal lobe damage, syringomyelia, myelopathy, mono- and polyneuropathy
d. disorders of motor pathways: Isaac’s syndrome, stiff-person  syndrome, tetanus, myotonic disorders, MMN
4. Misidentification of the subtype of dystonia (new classification –according Col-Cap concept and new CD patterns with involvement of muscles 
not routinely injected earlier)
5. Improper selection of active muscles (injections of muscles that are not responsible for specific pattern) and missing the muscles (no guidance, 
too short needles, too deep injections missing thin muscle layers, e.g. m. trapezius)
6. Lack of monitoring techniques of injections: us, emg (combination is the optimal method as visualization  does not mean that muscle is really active)
7. Improper adjustment of the total dose and its distribution in particular muscles
8. Subjective feeling of lack of improvement (dominating non motor symptoms like depression, anxiety, phobias or sleep problems)
9. Long-lasting dystonias causing secondary changes like myofibrosis, contractures
10. Improper storage and transportation of the medication
PSP — Progressive Supranuclear Palsy, MSA — Multiple System Atrophy, NBIA — Neurodegeneration with Brain Iron Accumulation, MMN — Multifocal Motor Neuropathy
3www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Małgorzata Tyślerowicz et al., Cervical dystonia — improving the effectiveness of botulinum toxin therapy
Proper identification of pattern of dystonia
One of the most common reasons behind therapy failures 
seems to be incorrect identification of the clinical pattern of 
CD. To properly identify the subtype of dystonia, the patient
should be examined carefully, not only in a relaxed seated
position when their upper body is in a resting state, but also
with open and closed eyes (because closing eyes can worsen
dystonic posture), standing and/or lying positions, while
walking or performing activities such as writing (these can
enhance dystonic movements).
By observing the patient from the side, the front, and also 
from the back, we can assess the change in head and neck 
position in each of the three planes. Sometimes an objective 
assessment may be difficult due to the activity of compensating 
muscles as well as coexistence of tremors and/or myoclonus. 
We should pay attention to the so-called ‘sensory twitches’ 
(as they may change the pattern temporarily), shoulder and 
scapula positions, and potential muscle hypertrophy and pain. 
If the arm is elevated, we should assess the patient by stabilising 
their arms by pushing down the elevated arm. This may reveal 
its compensating character to maintain the head erect position 
due to a severe head tilt.
The Col-Cap concept was first set out by Reichel et al. in 
2009 [23]. Their careful examination identified new patterns 
not previously recognised. Initially, CD had been classified 
into four types. These related to: turning the head (torticollis), 
tilting the head to one side (laterocollis), backwards (retrocol-
lis), or forwards (anterocollis). More than 50% of cases were 
diagnosed as torticollis, 10–15% as laterocollis or retrocollis, 
and less frequently anterocollis [24]. The ‘Col-Cap’ concept 
(collum-caput = neck-head) was invented on the basis of 
imaging examinations (CT/MRI of the head, cervical spine 
and also soft tissues) and functional anatomy. According to 
this approach, based on the various movements of the head 
(muscles insertions between skull and C2 spine level) and 
neck (muscles insertions between C2 and C7 level), 10 major 
subtypes of CD were identified (Fig. 1): transverse (torticaput/
collis), frontal (laterocaput/collis), sagittal with tilting forwar-
ds (anterocaput/collis) or backwards (retrocaput/collis) [25, 
26]. These distinctive patterns are ‘realised’ by the activity of 
different (i.e. different from those in the ‘classic four’) muscles 
involved in the particular type. So an inaccurate diagnosis 
may result in a lack of effect. According to the multicentre 
study recently published by Jost et al. analysing 306 consecu-
tive patients with CD, pure forms are rare (16.3%), whereas 
combinations of 2–6 of the subtypes are common (83.7%). 
Among all the subtypes, the most common primary form is 
torticaput (49%), and the second most common is lateroca-
put (16.7%) [27]. One can also distinguish combinations of 
incorrect positions such as a mixture of laterocollis to one side 
and laterocaput in the opposite direction; this is known as 
lateral shift. In addition, we see a combination of anterocollis 
and retrocaput called anterior sagittal shift, and consequently 
posterior sagittal shift as a combination of retrocollis and 
anterocaput.
To identify these new patterns, characteristic points/
lines should be identified, which enables levels of movement 
(collis, caput) to be distinguished. In the case of torsion, the 
main anatomical structures are: superior thyroid incisure of 
the larynx and manubrium of the sternum above the jugular 
incisure. Rotational torticollis is diagnosed if, during rotation, 
the larynx shifts in relation to the sternum. If these points 
remain in the same line, but the chin shifts in relation to the 
larynx, rotational head position is diagnosed (torticaput). 
In the sagittal plane, the meatus acusticus externus and the 
clavicula are useful anatomical landmarks. If only the ‘head’ is 
concerned, the meatus acusticus stays in line with the clavicula 
(anterocaput, retrocaput). If the projection is in front or behind 
the clavicula, the ‘neck’ level is involved (anerocollis/anteroca-
put) (Fig. 1) [28]. A treatment protocol differentiating the head 
and the neck level may result in better outcomes. However, to 
date this has only been shown in one retrospective study [29].
Based on the Col-Cap concept, ‘main’ muscles should be 
injected as the first choice, then ‘secondary’ in each subtype. 
In complex patterns, the leading (or primary) one should be 
first injected and in refractory cases previous injection patterns 
should be assessed and modified in the subsequent cycle [29].
Correct selection of active muscles 
and guided injections (US/EMG)
Before the Col-Cap concept, muscles were selected on the 
basis of functional anatomy, a physical examination accompa-
nied by assessment of muscle hypertrophy, location of pain, or 
arm elevation. Several published studies used electromyography 
(EMG) as an injection technique for the identification and lo-
calisation of muscles [30–34]. There are studies which strongly 
support the role of EMG showing that injections performed only 
according to anatomical landmarks can be imprecise (83% rea-
ched the sternocleidomastoid, but only 47% the levator scapule 
muscle) [35]. Moreover, EMG guidance increases the sensitivity 
and specificity of the muscle selection, even when performed by 
BoNT-A specialists. Clinical predictions of individual muscle 
involvement are only 59% sensitive and 75% specific without 
EMG use. It has been pointed out that muscular hypertrophy 
or shoulder elevation indicates ‘dystonic’ muscle activity in only 
70% of patients, showing how a classical physical examination 
can be confusing [36]. 
The role of EMG has been supported by randomised, 
blinded studies which have demonstrated that EMG-guided 
injections vs. anatomically-based bring significantly better re-
sults, measured by rating scales and subjective assessment: 82% 
(TWSTRS) and 61% (patients assessment) vs. 8% (TWSTRS) 
and 25% (patient report) respectively [34]. The same was 
proved in another study, which showed a significant difference 
in Jankovic scale (p = 0.05) between guided and blinded inje-
ctions [37]. Retrospective analysis confirmed the benefits of 
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using polymyography in groups of patients previously treated 
with BoNT with an unsatisfactory response. After one year of 
treatment, reasonable or good final results were obtained in 
60% of patients measured on both the Tsui Scale (p < 0.01) and 
the subjective assessment of patients (p < 0.001) [38]. Subsequ-
ently, one small open trial showed that EMG improved the tre-
atment outcome in 9/10 patients, demonstrating a significant 
improvement in TWSTRS (mean improvement of 64%) [39]. 
In contrast, there are studies which do not confirm the utility 
of EMG guided injections. In a systematic review by Nijmeijer 
et al., the average improvement on the Tsui Scale was greater 
(31.9 vs. 43.7%) in studies that used only clinical evaluation 
[40]. But because of profound differences in methodology, 
dosage, patient characteristics, and primary and secondary 
endpoints, no statistical analysis could be performed, and no 
firm conclusions could be drawn.
To sum up, a consensus of experts recommends a combi-
nation of clinical assessment and EMG examination as well 
Figure 1. Ten basic clinical patterns of cervical dystonia according to col-cap concept. A. Laterocollis, B. Laterocaput, C. Lateral shift (combi-
nation of laterocillis to one and laterocaput to opposite side), D. Torticollis, E. Torticaput, F. Anterocollis, G. Anterocaput, H. Sagittal-anterior 
shift (combination of anterocollis and retrocaput), I. Retrocollis, J. Retrocaput. Additional rare variant may be present (no picture) presenting 
as Sagittal posterior shift (combination of retrocollis and anterocaput). Courtesy of Via Medica and Jarosław Sławek, Monika Rudzińska eds, 
In: Toksyna botulinowa w praktyce neurologicznej, Via Medica, Gdańsk 2015, vol. 1, Fig. 2
5www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Małgorzata Tyślerowicz et al., Cervical dystonia — improving the effectiveness of botulinum toxin therapy
as EMG-guided injections in patients treated for the first 
time (Level  A) [34, 41]. But for those who have undergone 
unsuccessful treatment, EMG usefulness is less proven (Class 
III studies and Level C) [42, 43].
We must remember that EMG use does not allow us to dist-
inguish between ‘dystonic’ and compensatory muscle activities 
or to visualise the tip of the needle (the injector is not sure if 
the needle is positioned in the intended muscle). Such precise 
targeting of muscles can be achieved using other methods 
such as ultrasonography (US) or computed tomography (CT).
Ultrasound is an easily available, non-invasive method 
enabling the visualisation of muscles and surrounding stru-
ctures (nerve bundles and large vessels) in real time, which 
may increase the accuracy of injections of not only deep, but 
also superficial (sometimes as superficial as for example very 
flat trapezius) muscles. Studies regarding spasticity treatment 
with BoNT under US guidance have shown its efficacy in lo-
calising especially deep muscles. Recent publications are open 
studies conducted in small groups of patients or case studies 
on injections of deeply located muscles where the approach is 
challenging, such as the longus colli muscle or obliquus capitis 
inferior [41–44]. One of these studies assessed the impact of 
monitoring techniques such as US and/or CT in a group of 
eight patients requiring injections in deep cervical muscles (the 
obliquus capitis inferior, the longus colli muscle, obliquus capitis 
superior, scalenus anterior and scalenus posterior). The Tsui 
Scale confirmed a significant improvement occurring within 
four weeks (11.75 vs. 1.50) and on the TWSTRS scale in each 
of the subscales (20.0 vs. 5.25, 20.0 vs. 7.00, and 13.10 vs. 6.50) 
[48]. A study conducted in a group of five patients to assess 
the incidence of swallowing problems after injections revealed 
that an ultrasound examination, carried out in order to locate 
the EMG needle during injections in the sternocleidomastoid, 
significantly reduced such adverse effects (0% vs. 34.7%) (45). 
Nevertheless, no randomised, controlled studies have proved 
the greater effectiveness of US-guided versus blinded injections.
Muscles which seem to ‘benefit’ mostly from US moni-
toring include: suprahyoid muscles, scalenus muscles, the 
longissimus capitis and cervicis, semispinalis capitis and 
cervicis, obliquus capitis inferior (crucial muscles in some 
col-cap patterns), but also the sternocleidomastoid, levator 
scapulae, and trapezius (frequently injected too deeply) [46]. 
It seems that in some cases, particularly with accompany-
ing tremors or after several non-effective treatment attempts, 
EMG and US methods, applied simultaneously, should be 
considered [47]. The needle size should also be adjusted be-
cause one that is too short will not reach deep muscle layers, 
although these can be easily detected thanks to US guidance.
Optimal dosage and its distribution 
in particular muscles
The optimal dose of BoNT-A was obtained in pivotal 
studies. The recommendations according to SPC (summary 
product characteristics) are based on these clinical trials. 
However, dosage should be adjusted in subsequent treat-
ment cycles both in terms of effectiveness and safety. There 
are studies which indicate that efficacy and the incidence of 
side effects depend on the BoNT-A dose. A study assessing 
abobotulinumtoxin A showed that the largest and longest 
improvements were obtained in the 1,000U group [12]. Ne-
vertheless, the highest number of adverse events also occurred 
in this group. All groups (placebo, 250U, 500U and 1,000U) 
demonstrated improvements > 20% on the Tsui Scale after 
two weeks. However, in week 4 such improvements were still 
observed only in the 500 U and the 1,000 U groups. In these 
groups, also compared to the 250U and placebo groups, pa-
tients reported > 50% improvement on CGI scale statistically 
more frequently. Therefore, the experts’ recommendations, 
based on those studies [12, 48], suggest starting treatment by 
administering 500 U of abobotulinumtoxin. However, lower 
(200–400U) doses might be equally effective and safe if pre-
cisely administered e.g. under EMG guidance [49]. In clinical 
practice, the dose should be adjusted to muscle bulk and body 
mass, although formal studies have not been performed.
There are no randomised, controlled studies comparing 
the effectiveness of the number of injections per muscle. 
A comparative study on 49 patients showed that multi-point 
injections increased treatment effectiveness: they reduced 
pain (p < 0.002), increased the range of motion (p < 0.001), 
and lengthened the duration of effect (p < 0.001) [50]. Experts 
recommend distributing the dose to 1–4 points, depending on 
the area of the muscle [51].
Subjective feelings of lack of improvement 
and non-motor symptoms
Patients suffering from cervical dystonia, like those with 
other movement disorders, present a wide spectrum of non-
-motor symptoms which have not been considered in clinical
trials assessing BoNT-A effectiveness, but may influence the
overall result of therapy.
Patients with CD appear to be more aware of having abnor-
mal dyskinetic movements than do patients with Huntington’s 
or Parkinson’s Diseases [52]. Non-motor symptoms have been 
noted in several studies: 61.8% of patients with CD presented 
lack of self-confidence due to stigmatisation, 59.8% had sleep 
problems, and 51% fatigue [53]. Depression was prevalent in 
as many as 47.5% of patients and this was the major determi-
nant of poor quality of life [3]. In another study, poor quality 
of life was more common in CD than in blepharospasm and 
writer’s cramp and also depression and anxiety were the major 
correlates [54].
Depression, along with other emotional-psychological di-
sorders, may constitute a clinical spectrum of CD independently 
of motor symptoms. Mood disturbances coupled with anxiety, 
also adjustment disorders or obsessive-compulsive behaviours, 
occur significantly more often in patients with focal dystonias 
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(57.3% of patients with dystonia, compared to 24.1% of healthy 
subjects and 34.6% of patients with hemifacial spasm) [55]. 
Another study showed that patients with CD are much more 
frequently affected by depression (15–53.4%) and anxiety di-
sorders (26.4– 83.3%), and 4.5 times more often by agoraphobia 
or panic attacks than the general population. No correlation 
was found between age, duration of dystonia or its severity, as 
well as duration of BoNT-A treatment, which may indicate that 
mental disorders are primary, but not secondary, to dystonia. 
A study by Berardelli et al. showed that during a five-year 
follow up of treatment with BoNT injections, it significantly 
improved dystonic movements (TWSTRS 33.4 +/- 11.1 at 
baseline, 26.9 +/- 10.9 after five years). However, the incidence 
of neuropsychiatric disorders did not improve at all (65% at 
baseline, 64% after five years), which suggests an independent 
mechanism and, possibly, the need for additional treatment 
[56]. A similar effect was observed in Sławek et al.’s study, 
showing in a group of 101 patients with CD treated with 
BoNT-A that size effect for TWSTRS (motor presentation) was 
significant after treatment: 1.1 (SD ± 0.6), but for depression 
(Montgomery Åsberg Depression Rating Scale) it was only 
0.5 (SD ± 0.7) [4].
Stamelou et al. presented evidence indicating an important 
non-motor component to primary dystonia, including abnor-
malities in sensory and perceptual functions, as well as the neu-
ropsychiatric, cognitive and sleep domains [57]. Widespread 
loss of inhibition and pathologically increased plasticity appear 
to play important roles in the pathophysiology of primary 
dystonia [58]. The hypothesis is that non-motor features of 
dystonia could be explained by a common pathophysiologi-
cal deficit that also underlies the motor symptoms [59–61]. 
Genetic susceptibility is the key to the pathophysiology of 
dystonia, indicated by the numerous non-motor abnormalities 
that are found in unaffected first-degree relatives of patients 
with adult-onset focal dystonia and non-manifesting gene 
mutations carriers. This genetic background may predispose 
patients to develop dystonia in the presence of other factors 
that may have important non-motor components, such as 
repetitive activity, trauma, or emotional distress [61].
Considering the accompanying non-motor disorders, such 
as pain or a broad spectrum of psychiatric diseases, it seems 
that analgesics or antidepressants would be beneficial. There 
are, however no controlled studies supporting such practice. 
The only randomised, controlled trial conducted recently 
looked at the efficacy of escitalopram in the treatment of 
CD with concomitant tremor. It did not reveal any beneficial 
effects of the drug on either motor or non-motor symptoms; 
the authors underline however that this should not be a reason 
for resigning from such therapy [62].
Primary and secondary immunoresistance
Patients who do not respond to the therapy can be classi-
fied as those who did not respond at all from the beginning 
(so-called primary non-responders, PNR), or those who 
stopped responding to the treatment after a good initial effect 
(so-called secondary non-responders, SNR). 
It is suspected that primary resistance may be associated 
with preexisting BoNT-A antibodies (AB), chronic exposure to 
BoNT-A in childhood, or cross-reaction of other AB (tetanus 
toxin AB) [63, 64]. However, this is only speculation unsup-
ported by studies. Secondary non-responsiveness is defined 
differently by different authors. Some authors claim that two 
consecutive ineffective treatment cycles (i.e. no subjective 
improvement or exacerbation by at least 2 points on the Tsui 
Scale as well as absence of side effects typical for BoNT-A) 
which occur after at least two effective cycles in the past (defi-
ned as improvement on the Tsui Scale by at least 3 points and/
or atrophy in injected muscles and/or an occurrence of side 
effects typical for BoNT-A) are enough to diagnose secondary 
resistance [18]. Others believe that secondary resistance can 
be diagnosed only after three consecutive ineffective treatment 
cycles [65]. One should remember that it may be a pseudoim-
munoresistance due to other reasons mentioned earlier, and 
that the real one should be confirmed in laboratory or clinical 
tests (see below).
It is estimated that secondary resistance affects approxima-
tely 3–5% of patients [66]. Previously the production of AB to 
BoNT-A was considered the main cause of secondary treatment 
failure (STF). Some publications indicate that higher BoNT-A 
doses, administered at shorter intervals and frequent injections 
(within six weeks of the previous injection, so called booster 
injections), increase this risk of development of AB [67, 68]. 
Most of the previous studies reporting AB in groups of CD 
patients were unbiased regarding STF and had a short duration. 
Therefore, AB rates reported in these studies more or less repre-
sent the incidence of AB induction during 1-2 years of therapy 
and the range is between 0.5% and 2.0% [69–71]. In long-term 
treated patients with CD, the prevalence of AB is higher, indi-
cating 14% in the group of patients still responding to therapy 
who underwent BoNT-A injections over 10 years [72]. Another 
study showed that duration of treatment of ~15 years carries 
a risk of up to 40% of becoming AB positive, not influencing the 
treatment result. In addition, the study showed that single dose 
per session and BoNT-A formulation were the most significant 
factors influencing AB formation [73].
Furthermore, the amount of complexing proteins, which 
differs in the three most commonly used preparations, plays 
an essential role. Antibodies were found in 9.5% of patients 
treated only with original onabotulinumtoxinA with a large 
amount of complexing proteins (100 U/25ng protein), whe-
reas AB were not detected in any patients treated exclusively 
with the new preparation of onabotulinumtoxinA (100U/5ng 
protein) marketed more than 20 years ago [74]. Antibodies 
were not found in patients treated with incobotulinumtoxinA, 
which does not contain complexing proteins [75, 76].
Neutralising antibody titre decreases after discontinuation 
of therapy. The rate of decline differs for each individual, and 
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the decline can last for up to four years. Minimum 12-week 
intervals between injections are still advisable. However, some 
studies on incobotulinumtoxinA reveal that shorter intervals 
are also safe and do not produce antibodies [19].
In summary, studies show that AB and their titre do not 
necessarily contribute to secondary resistance; subsequent 
studies revealed that antibodies are found in approximately 
50% of patients with secondary resistance [77, 78] and the 
reasons for this situation possibly differ.
According to some studies, secondary resistance could be 
associated with a higher dose of BoNT-A, administration of 
other therapies (rehabilitation, pharmacological treatment), 
a significant number of side effects, and more frequent inter-
ruptions in BoNT-A treatment [79].
The lack of response due to the neutralising antibodies 
formation may be diagnosed with specific tests. MPA (mouse 
protection assay), HDA (hemidiaphragm assay (HDA), and 
new enzyme-linked immunosorbent assay (ELISA) are cur-
rently available. According to the latest reports, a combina-
tion of ELISA and HDA is a quick method characterised by 
the highest sensitivity and its price is reasonable. For 100% 
sensitivity its specificity is 90%, and for 100% specificity its 
sensitivity is 55%. Sensitivity of previously used tests, such as 
MPA or WBA (western blot assay) was lower and ranged from 
33% to 53% [80].
Instead of laboratory tests, in clinical practice we can use sim-
ple, objective tests involving a unilateral application of BoNT-A in 
the frontal muscle [74] or in the extensor digitorum brevis muscle. 
The frontal test is performed by administering 30 units of abo-
botulinumtoxinA or 10 units of ona/incobotulinumtoxinA [71] 
in the frontalis muscle on one side. Clinical assessment (ability 
to raise eyebrows) is recommended after 2–4 weeks. Asymmetry 
indicates that BoNT-A is effective [43]. For an extensor digitorum 
brevis muscle test we administer 100U of abo- or 20 units of ona-
botulinumtoxinA in this muscle and assess the compound muscle 
action potential response (CMAP) by stimulating the peroneal 
nerve at baseline and two weeks after injection (CMAP should 
more than halve compared to its original value). For a decline 
of up to 20%, immunoresistance is quite probable; for values of 
20–50%, the result is doubtful [81].
In patients with immunoresistance, we can discontinue 
injections for 12–18 months and observe the patient at regu-
lar intervals. If dystonia significantly reduces quality of life, 
an alternative is re-administration of BoNT-A. Or one may 
consider the use of botulinum toxin B, which is safe and ef-
fective in the treatment of cervical dystonia, but presents high 
immunogenicity potential, in particular in patients already 
resistant to BoNT-A treatment [82, 83].
Intrinsic muscle changes  
and change of dystonia pattern
Muscle fibrosis and contractures, being the result of long-
-lasting disease as well as a change in the pattern of dystonia,
play an important role in secondary resistance apart from 
immunisation. The muscular dystonia pattern may change 
in some patients over time. BoNT-A injections may ‘activate’ 
other previously inactive muscles (contributing to the similar 
clinical pattern of dystonia), which implies the activity of a cen-
tral mechanism, conditioning the position of the head or neck 
through non-specific muscle activation. The clinical pattern 
of dystonia in the course of the disease can also change. This 
probably results from activation of other muscles, which in 
turn results from a peripheral block of initially active dystonic 
muscles, or a change of the activation centre at the level of the 
central nervous system [84–86].
Evaluating the effectiveness of treatment
A lack of improvement in a patient’s assessment may 
contradict the positive change in rating scales. The most 
commonly used are Tsui, CIDP-58 and TWSTRS.
The TWSTRS is most commonly used in clinical trials and 
serves as the primary endpoint for assessing the effectiveness 
of BoNT-A in treating CD [14, 17, 87–90]. In most studies, an 
improvement by 25–30% measured with this scale is conside-
red significant. It shows a strong correlation with the Tsui Scale 
[91]. Despite many advantages however, it does not take into 
account the evaluation of dystonic tremor; there is no clear 
definition of the midline and the full range of motion [92]. 
This scale also cannot assess properly the complex patterns of 
CD demonstrated in the Col-Cap concept. 
In addition, due to its complex nature, the scale can hardly 
ever be applied in everyday practice. The authors of one recent 
study determined the number of points in the TWSTRS scale 
which contributes to a minimally clinically perceptible change 
in the Patient Global Impression of Change (PGIC) scale: 
a change by 3 points in milder cases (≤ 28.5) and 18 points in 
severe cases (> 52) [93]. A linear relationship was also found 
between the TWSTRS total scores and the PGIC: an impro-
vement by 2.9 points in the TWSTRS scale corresponded to 
a change by one category in the PGIC scale.
The lack of a specified rating scale including both motor 
(with respect to the new Col-Cap patterns) and wide spectrum 
of non-motor CD features seems to be an unmet need. Moreo-
ver, it may create difficulties when planning new studies [94].
The next unmet need is the lack of consensus on specific 
rehabilitation programmes dedicated to CD patients and aimed 
at enhancing the effect of BoNT-A therapy.
In conclusion, CD treatment with BoNT-A remains a chal-
lenge for the physician. It is rare to obtain satisfactory effects 
at the first session. If unsuccessful, the long list of possible 
reasons, which have been the subject of this paper, should 
be considered.
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